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cuTTing funds for oraL conTracePTives:  
vioLaTion of equaL ProTecTion righTs and The disParaTe 




Cutting funding for oral contraceptives has far reaching 
implications for women, including adverse impacts on women’s 
health, negative economic impacts on society, and constitu-
tional violations. In a country whose governmental health plans 
(Medicare and Medicaid) reimburse men’s costs for Viagra®,1 it 
is hardly appropriate to deny women access to prescribed oral 
contraceptives that have traditionally been defined as supplemen-
tary services falling under the umbrella of primary care.2 Due 
to the wording of a provision within the Deficit Reduction Act 
of 2005, some contend that non-profit clinics and campus health 
centers can no longer offer oral contraceptives at reduced rates.3 
This article will show how decreasing funding for oral contracep-
tives violates equal protection and embodies a disparate impact 
in relation to women’s health for Medicaid and Title X beneficia-
ries—low-income Americans who would benefit from access to 
contraceptives and other preventative health-care services. 
Part I of this article addresses the history, uses, and eco-
nomics of oral contraceptives. Part II highlights the government’s 
role and policies in funding oral contraceptives over the past 35 
years. Part III discusses the present regulatory landscape, includ-
ing The Deficit Reduction Act of 2005 (“DRA”), the Department 
of Health and Human Services (“DHHS”) proposed regulations, 
Prevention Through Affordable Access Act, and Title X. Finally, 
Part IV shows how the history, politics, and regulations culminate 
in a violation of the Constitutional right to equal protection.
i. oraL conTracePTives: hisTory,  
uses, economics
a. HiStory
Oral contraceptives are relatively recent forms of con-
traception.4 Between 1950 and 1954, Gregory Pincos, a scientist, 
and John Rock, a renowned Harvard obstetrician and gynecolo-
gist, developed a chemical contraceptive and performed the first 
human clinical trial.5 The “Pill” regime that they established (21 
days on progesterone to inhibit ovulation, 7 days to menstruate) 
is still in use today.6 The “Pill,” called Enovid, was approved by 
the United States Food and Drug Administration (“FDA”) for the 
treatment of severe menstrual disorders.7 
In the 1960’s, the FDA approved the first oral birth con-
trol pill.8 The FDA required Searle pharmaceutical company 
to complete field trials for all doses of its oral contraceptive, 
Enovid.9 Ortho Pharmaceutical introduced its first oral contra-
ceptive in 1963. By 1965 the “Pill” became the leading method 
of pre-conceptual and reversible contraception in the United 
States.10 
During the 1970’s, United States Senator Gaylord 
Nelson convened Senate hearings on the safety of the “Pill.”11 
The FDA ordered that all oral contraceptive packages contain 
information detailing possible side effects.12 By 1988, the FDA 
recognized additional potential benefits of oral contraceptives, 
including decreased incidence of the following: ovarian cancer, 
endometrial cancer, pelvic inflammatory disease, ovarian cysts, 
and benign breast disease.13 
In the twenty years since the FDA recognized additional 
potential benefits of oral contraceptives, manufacturers have 
received FDA approval to use oral contraceptives for the treat-
ment of acne and for the severe condition of premenstrual dys-
morphic disorder (“PMDD”).14 Oral contraceptives have been 
used to treat a variety of conditions and are proven to positively 
affect many aspects of women’s health, including preserving 
fertility. 
b. uSeS anD beneFitS oF birtH Control pillS
Over the past 50 years, the FDA has recognized poten-
tial benefits in the area of women’s health, such as decreased 
incidence of the following: ovarian cancer, endometrial cancer, 
pelvic inflammatory disease, ovarian cysts, mid-cycle pain (dys-
menorea), heavy bleeding and benign breast disease.15 Manu-
facturers have also received FDA approval to distribute oral 
contraceptives for the treatment of acne and for PMDD.16 Physi-
cians regularly prescribe oral contraceptives for other debilitat-
ing conditions such as polycystic ovarian syndrome (“PCOS”), 
and endometriosis.17 These conditions, as well as PMDD, may 
cause irregular menstrual cycles, increased risk of high blood 
pressure, diabetes, high cholesterol, and infertility. These physi-
cal and emotional conditions may be mitigated by taking oral 
contraceptives, which are proven to preserve fertility.
One of the most threatening conditions to a woman’s 
fertility is endometriosis, a condition in which deposits of endo-
metrium (uterine lining) are found outside the uterus.18 It is a 
common disorder, yet it is one of the most enigmatic gynecologic 
diseases.19 Endometriosis occurs when endometrial tissue outside 
the uterus responds to changes in hormones,20 breaking down and 
bleeding like the lining of the uterus does during the menstrual 
cycle.21 This breakdown of tissue often creates adhesions (scar 
tissue), which causes tremendous pain and binds surrounding 
organs together.22 Aside from surgery, the most common way to 
control symptoms of endometriosis and shrink existing implants 
is through the use of oral contraceptives.23 
As indicated, the uses of oral contraceptives extend 
far beyond the indication for contraception. Ironically, PMDD, 
PCOS, and endometriosis have been shown to cause infertility.24 
Oral contraceptives, however, have been shown to temper these 
conditions enabling a woman to retain her reproductive abilities.25 
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C. tHe eConomiCS oF birtH Control
The present cost of oral contraceptives is high.26 The 
cost to society, however, of preventing college students and low-
income women from purchasing them at a reduced rate is even 
higher.27 In 2004, researchers estimated a net public savings of 
$4.3 billion by clinics through averting 1.4 million unintended 
pregnancies.28 This number does not include the costs of infertil-
ity treatments or the cost to treat the escalation of other diseases 
(Type 2 diabetes and cardiovascular disease) not associated with 
PMDD, PCOS, and endometriosis.29 
Funding from Medicaid programs and Title X of the Pub-
lic Health Service Act has helped millions of women maintain a 
healthy reproductive life.30 In fact, almost 
seventeen million women in the United 
States utilized these publicly subsidized 
services in 2002.31 The federal and state 
governments spent a combined $1.26 bil-
lion on reversible contraceptive services.32 
Yet, despite these health benefits and sub-
stantial savings, the government enacted a 
provision that has forced pharmaceutical 
companies to stop providing oral contra-
ceptives at reduced rates.33 
At a time when demand for sub-
sidized contraceptives has increased, public funding for family 
planning clinics has stagnated.34 Exacerbating this situation is the 
unwillingness of many pharmaceutical companies to continue to 
provide oral contraceptives to the public system funded by Title 
X at a relatively low cost.35 This appears to be the result of the 
2005 DRA revamping the average manufacturer price (“AMP”) 
formula and altering the 340B drug-pricing program. The Omni-
bus Reconciliation Act of 1990 established AMP and Best Price 
for use in the Medicaid program.36 Thereby, sales by a manufac-
turer of covered outpatient drugs below ten percent of AMP were 
generally excluded from Best Price.37 In 1992, the 340B program 
that was created when the Public Health Services Act (“PHSA”) 
was amended to require pharmaceutical manufacturers to provide 
prescription drugs at reduced prices to “covered entities.” 38 
Calculating pharmaceutical costs for a 340B program 
is a semi-complex formula based on the AMP that is provided to 
the Center for Medicare/Medicaid Services (“CMS”).39 AMP is 
defined as “[t]he average price paid to manufacturers by wholesal-
ers for drugs distributed to the retail pharmacy class of trade.” 40 
The lowest price available from “the manufacturer to any whole-
saler, retailer, provider, health maintenance organization, or non-
profit or government entity, with some exceptions” is considered 
the Best Price.41 Although Best Price is required to be reduced 
to account for price adjustments such as rebates and discounts, it 
does not include prices charged to certain federal purchasers.42 
The two factors involved in calculating 340B price are the AMP 
and a “rebate percentage” (consideration of both the AMP and 
the Best Price reported to CMS).43 This calculation is the “ceil-
ing price” formula for brand name pharmaceuticals (AMP for the 
previous month—15.1% discount off the AMP) considered by 
CMS.44   
Beginning in 2007, seemingly small language changes 
in the DRA impacted the calculation of AMP, Best Price, and 
limited the number of facilities that qualify for discounted 
prices on birth control.45 The concerns over that the AMP, which 
pharmaceutical companies providing covered outpatient drugs are 
required to calculate and submit to CMS, is not affected by the 
increase in customary portion of the new formula were directed 
at how pharmacies would be reimbursed.46 The Office of the 
Inspector General (“OIG”) and the General Accounting Office 
(“GAO”) found that this new formula may “result in reimburse-
ments to pharmacies that are below pharmacy acquisition costs.” 
Specifically, the DRA of 2005 requires manufacturers to report 
AMP and Best Price to CMS on a monthly basis compared to the 
previous quarterly basis and imposes several important changes 
regarding AMP and Best Price calculations.47 However, the act 
has a provision that extends the “exclusion of customary prompt 
pay discounts [to wholesalers].” 48 This means that the AMP is 
not affected by the increase in customary 
prompt pay wholesaler discounts.49 There-
fore, the language should have no effect 
on pharmaceutical manufacturers ability 
to continue providing oral contraceptives 
to public health and campus health clin-
ics, because the prices these facilities pay 
are not included in the AMP, Best Price, or 
ceiling price calculations. 
Equally important is the limitation 
that certain entities will be excluded from 
the calculation of the AMP and the “rebate 
percentage” on which pharmaceutical companies base their prof-
its.50 These entities include those defined in section 340B(a)(4) 
of the Public Health Service Act; intermediate facilities for the 
mentally retarded; a State-owned or operated nursing facility; 
and any other entity determined by the Secretary of DHHS to be 
a safety net provider.51 The Office of Pharmacy Affairs oversees 
the 340B pricing program and its administration.52 Entities that 
have been identified as qualifying 340B organizations under the 
Social Security Act and the Public Health Services Act (“PHSA”) 
include: federally-qualified health centers; a family planning 
project receiving a grant or contract under Section 1001 of the 
PHSA; and any entity receiving assistance under section 318 (42 
USCS § 247c) (relating to the treatment of sexually transmitted 
diseases).53 
Even if campus health centers do not qualify as 340B 
organizations, the Secretary of DHHS has the discretion to deter-
mine what facilities qualify as safety net providers to which the 
sales of drugs at nominal prices would be appropriate based upon 
four factors.54 The factors are: 1) facility or entity type; 2) the 
nature of the services provided; 3) the patient population served; 
and 4) the number of other facilities or entities eligible to pur-
chase at nominal prices in the same service area.55 Based upon 
these criteria, it is reasonable for the Secretary to include campus 
health centers as qualifying entities.
By interpreting the language to mean a 340B quali-
fying facility does not include community health and college 
health centers as an exclusion when calculating the AMP and the 
“rebate percentage,” and interpreting the language that exempts 
certain “safety net providers” to exclude family planning clinics; 
pharmaceutical manufacturers, including Organon, the maker of 
Cyclessa® and Desogen® oral contraceptives, made an economic 
decision not to provide drugs at a discounted rate.56 Despite the 
company being unhappy about increasing the prices for colleges, 
“Nick Hart, Organon’s executive director of contraception, says 
they were forced to make ‘a business decision’ after the law went 
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into effect.” 57 As a result, women who were paying between 
$3–$10 per month for oral contraceptives are now paying nearly 
900% more for the same prescription.58 
Sadly, this price increase was unnecessary. The deci-
sion of pharmaceutical companies to stop offering low-priced 
oral contraceptives to health centers and clinics was an inde-
pendent decision that the DRA of 2005 did not mandate.59 On 
the contrary, four types of entities, including 340B qualifying 
facilities and certain safety net providers determined by the Sec-
retary of DHHS, were excluded from the best price determina-
tion (meaning that pharmaceuticals offered at reduced rates to 
these four types of entities would not be included in the price 
determination).60 Additionally, Congress passed a provision to 
delay the application of new payment limits for multiple source 
drugs under Medicaid until September 30, 2009.61 Therefore, the 
AMP or the “ceiling price” is not impacted by the DRA.62 
Pharmaceutical companies’ interpretations of the DRA 
of 2005 have affected over three million college and low-income 
women.63 Many hard-working women can no longer access FDA 
approved methods of birth control, including oral contracep-
tives.64 The only entities benefiting are manufacturers and savvy 
entrepreneurs through higher prices and arbitrage opportunities.65 
Overall, there is no logical explanation for repealing access to 
low price oral contraceptives based on the statutory language of 
the DRA of 2005.
ii. governmenT funding and PoLicies reLaTed  
To oraL conTracePTives
It is hard to fathom that President Dwight Eisenhower 
stated in 1959 that birth control “is not a proper political or gov-
ernment activity or function or responsibility” and emphatically 
added that it is “not our business.” 66 Only five years later, Presi-
dent Lyndon B. Johnson pushed legislation for federal support 
of birth control for the poor.67 During the Nixon administration, 
this trend continued.68 Title X of the Pub-
lic Health Services Act (“Family Planning 
Services and Population Research Act of 
1970”) authorized the Secretary to make 
grants to and enter into contracts with pub-
lic or nonprofit private entities to assist in 
the establishment and operation of volun-
tary family planning projects, appropriat-
ing $180 million between 1971 and 1973.69 
The only method of birth control not 
entitled to funds was a surgical abortion 
because it was not considered a preventive 
family planning service.70 Under the Ford Administration, Con-
gress extended grants for comprehensive public health services71 
and expressly defined “community health centers” as entities that 
provide primary health services and referrals to providers of sup-
plementary health services.72 Primary health services included 
family planning, and supplemental health services included phar-
maceutical and health education services.73 The Secretary could 
“make grants to public and nonprofit private entities for projects 
to plan and develop community health centers which will serve 
medically underserved populations.” 74 Clearly, there was a com-
mitment to ensure that women received the care and treatment 
they needed to preserve their reproductive health.
Under the Reagan Administration, public and nonprofit 
entities encountered a setback in funding, in light of the conflict-
ing interpretations of Title X equating oral contraception with 
surgical abortions.75 However, the language, on its face, confirms 
that the intent of Congress was not to equate the two.
In 1988, the Secretary of DHHS promulgated new regu-
lations to differentiate between Title X programs and abortions,76 
emphasizing that “the purpose and the demonstrated effect of con-
traceptive counseling is to promote the use of contraception.” 77 
Unfortunately, DHHS also adopted regulations (the “Gag Rule”) 
prohibiting Title X facilities from providing information, coun-
seling, or referrals concerning abortions.78 During the first 18 
years of the Title X program, the Act was interpreted to mean that 
the funds could not be used to perform abortions, but it did not 
restrict the ability of clinics to provide counseling or referrals.79 
In 1991, the Supreme Court stipulated that, by clearly 
defining “family planning,” the regulations clarify that Congress 
intended Title X funds to be expended to support preventive fam-
ily planning services.80 According to the General Accounting 
Office, the majority of clients of Title X-sponsored clinics are not 
pregnant and their services include and were restricted to physi-
cal examinations, education on contraceptive methods, precon-
ceptional counseling, and general reproductive healthcare.81 The 
Clinton Administration recognized that, while abortions are not a 
method of family planning, the “Gag Rule” endangered women’s 
lives and health by preventing them from receiving accurate med-
ical information from their physicians.82 Consequently, the “Gag 
Rule” was repealed.83 
iii. The PresenT reguLaTory LandscaPe’s  
roLe in The crisis
Without publicly funded clinics providing contraceptive 
services, there would be 1.4 million more unintended pregnan-
cies and 49% more abortions annually in the United States.84 
Moreover, for every $1.00 spent to provide 
services in the nationwide network of pub-
licly funded clinics, $4.02 is saved in Med-
icaid birth costs.85 
Unfortunately, the pharmaceuti-
cal companies’ unwillingness to offer oral 
contraceptives at nominal prices to publicly 
funded clinics has created a birth control cri-
sis.86 Now, millions of women are paying up 
to nine or ten times what they were paying 
before, if they can afford it.87 The compa-
nies’ decisions undermine the benefits under 
Title X and are detrimental individually on women’s reproductive 
health and collectively on our nation’s economic welfare.88 
a. title x v. Dra
Statutes or provisions relating to the same individual 
or class of individuals, or to a closely allied subject or object 
may be regarded under the rule of in pari materia,89 to ascer-
tain and effectuate Congressional intent by proceeding upon the 
supposition that several statutes were governed by one spirit and 
policy and were intended to be consistent and harmonious.90 
In the present case, Title X and section 6001 of the DRA, both 
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provisions related to funding, should be read together for the 
intent of  providing funding so all women could have access to 
reproductive healthcare, family planning, and preconceptional 
birth control.91 
1. title x: settled Policy
Since 1970, the purpose of Title X has been to assist in 
making voluntary family planning services available to all per-
sons by enabling public and non-profit private entities to plan and 
develop comprehensive programs. Understanding the need for a 
high standard for ethical delivery of services, Title X required 
that clients be offered a broad range of contraceptive methods.92 
Today, Title X supports approximately 4,400 out of 7,700 family 
planning clinics, serving nearly five million women.93 The cur-
rent guidelines were developed in conjunction with the American 
College of Obstetricians and Gynecologist (“ACOG”) and require 
a complete physical exam (including Pap test) and education 
about the importance of preventive care.94 Title X is indicative 
of settled policy that women should have access to reproductive 
healthcare, family planning, and preconceptional birth control. 
2. 2005 dra – effective January 2007
An unintended consequence of the DRA, specifically 
Section 6001, is that health centers no longer receive prescription 
contraceptives at a nominal or base price. Because there is a pro-
vision in the DRA that insulated publicly funded health clinics 
from paying a higher premium and in turn exempted these prices 
from the AMP calculations, there is no acceptable explanation 
for this consequence. The only explanation proffered by the phar-
maceutical companies is that they made a “business decision” to 
no longer follow established legislative precedent. Furthermore, 
Congress has done nothing since the implementation of the DRA 
to rectify the situation. The result is that the objective of Title X 
and Medicaid is being undermined while pharmaceutical manu-
facturers are realizing higher profit margins.
The provisions in section 6001 of the DRA should be 
construed to mean that because of the “safe harbor” exempting 
nominal sales pricing to certain entities from being included in 
the calculation, Congress intended to preserve the Title X objec-
tive, while not adversely impacting the reimbursement of phar-
maceuticals through Medicaid. It is imperative that Congress 
continue to uphold the original legislative intent of providing 
access to high quality contraceptive services and preventive care 
to young and low-income citizens.95 
b. DHHS initiativeS to unDermine women’S 
reproDuCtive HealtHCare FunDing
In the summer of 2008, the Bush Administration called 
on DHHS to draft new rules that would severely restrict women’s 
healthcare options by defining “abortion” so broadly that it would 
encompass many types of birth control, including oral contra-
ceptives.96 The DHHS proposal defined abortion as “any of the 
various procedures—including the prescription, dispensing and 
administration of any drug or the performance of any procedure 
or any other action—that results in the termination of the life of 
a human being in utero between conception and natural birth, 
whether before or after implantation.” 97 This definition defies 
Congressional intent and the Supreme Court’s interpretation of 
abortion.98 
In addition to posing serious threats to the reproductive 
health of millions of uninsured and low-income Americans, the 
language could prevent health facilities from guaranteeing their 
patients access to the full range of comprehensive reproductive 
healthcare.99 On July 15, 2008, several Senators signed a letter 
addressed to the Secretary of DHHS urging reconsideration of 
the regulations.100 One argument was that the proposed defini-
tion would allow common forms of contraception such as the 
birth control pill to be classified as abortion, thereby denying 
contraception to women who need it.”101 In a follow-up letter, 
they emphasized the medical definition of pregnancy,102 spe-
cifically that a pregnancy does not begin until a fertilized egg 
implants itself to the uterine wall,103 and most modern forms of 
birth control work by blocking implantation.104 Calling a pre-
implanted fertilized egg a “human being in utero” is incorrect.105 
Ultimately, confusing the definitions of contraception and abor-
tion would wreak havoc on law, regulations, and policy.106 
C. prevention tHrougH aFForDable aCCeSS aCt 
The Prevention Through Affordable Access Act was 
introduced in the House of Representatives107 to clarify any ambi-
guity in the DRA language and protect student health centers and 
public or nonprofit private entities providing health services.108 
It received bipartisan support and aimed to “rectify an allegedly 
flawed condition in the DRA, which caused national pharmaceu-
tical companies to stop selling birth control to college clinics [and 
publicly funded health clinics] at discounted prices.”109 Both the 
House and the Senate versions of the bill were introduced and 
referred to Committees nearly a year ago.110 No other action has 
been taken since the initial introduction.111 
iv. The 2005 dra – vioLaTion of equaL 
ProTecTion 
In December 1961, it was still a crime to use birth con-
trol in Connecticut.112 Boldly, C. Lee Buxton, M.D. and Estelle 
Griswold opened four Planned Parenthood Clinics.113 Their arrest 
brought national attention to anachronistic state laws, which cul-
minated in a 7–2 ruling by the United State Supreme Court that 
Connecticut’s law prohibiting the use of birth control was uncon-
stitutional, violating a couple’s right to privacy.114 Eisenstadt v. 
Baird made it clear that a state cannot impede the distribution of 
birth control to an unmarried person, thus striking down a Mas-
sachusetts law.115 Less than a year later, the Supreme Court ruled 
on one of the most controversial issues of our time—abortion.116 
These judicial precedents not only set the tone for the adoption 
of Title X, but also laid the foundation for recognizing women as 
a protected class.
a. equal proteCtion analySiS
The fundamental question under consideration is 
whether there is something in the DRA requiring pharmaceutical 
companies to no longer offer nominal pricing on oral contracep-
tives to public, non-profit, and campus health clinics. The Equal 
Protection Clause of the United States Constitution provides 
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that no person shall be denied the equal protection of the law.117 
Fundamentally, equal protection deals with “governmental clas-
sifications that deprive a certain class of persons of benefits that 
persons in other classes are entitled to receive, or that subject 
a certain class of persons to burdens that are not imposed on 
persons in other classes.”118 By making oral contraceptives 
unavailable because of the exorbitant cost, women are the class 
of persons being deprived of benefits of reproductive healthcare 
and family planning they are entitled to under Medicaid and Title 
X.119 Although men also use the same federally funded centers, 
they do not carry the burden of paying more for prescriptions 
under the DRA.
On its face, the DRA does not discriminate because it 
contains no explicit gender classification language.120 However, 
just because it is facially neutral does not mean it is free from dis-
crimination. The difference is that courts will not merely assume 
that the DRA is intentionally discriminatory; instead, evidence 
of discrimination must be found through its administration and 
purpose or effect.121 In Yick Wo v. Hopkins, the Supreme Court 
held that even if a law “be fair on its face and impartial in its 
appearance, [equal protection will still be violated] if it is applied 
and administered by public authority with an evil eye and an 
unequal hand.”122 There, equal protection was denied when the 
discrimination and public administration of the law was found 
to be illegal. 
Personnel Administrator of Massachusetts v. Feeney 
dealt with discriminatory intent in the purpose and effect of a law 
giving preferential treatment to veterans.123 There, the Supreme 
Court asserted that proof of discriminatory “impact provides ‘an 
important starting point,’ but purposeful discrimination is the 
condition that offends the Constitution.”124 
The DRA must be considered in pari materia with Title 
X and Medicaid when considering the administration and pur-
pose and effect of the law. The situation of women being denied 
access to affordable oral contraceptives because of the AMP cal-
culation is akin to the situation in Yick Wo and distinguishable 
from Feeney. In fiscal year 2006, the Medicaid program spent 
$1.3 billion for family planning services, and Title X funds con-
tributed $215 million to approximately 7,683 clinics.125 Each 
year, approximately seven million women received contracep-
tive services.126 Of the total number of 
patients treated, men accounted for only 
5% of the overall caseload.127 Here, 
Congressional intent points toward 
the “evil eye and unequal hand” and 
“purposeful discrimination” because 
Congress knew the DRA AMP formula 
was being applied in a way that denied 
women access to oral contraceptives to which they were entitled 
under federal programs.128 Congress also knew of executive ini-
tiatives to equate oral contraceptives to a surgical abortion.129 
Therefore, the discrimination against women, public administra-
tion, and purpose and effect of the DRA should be violations of 
equal protection.
For purposes of the DRA, the classifying factor distin-
guishing between two similarly situated classes is gender, which 
receives intermediate scrutiny. Men’s access to prescriptions 
related to reproductive health has not been rendered inaccessible 
due to cost while women’s prescriptions for oral contraceptives 
have been affected by the DRA. 
When assessing a statute under an intermediate scru-
tiny level of review, two operative parts must be considered—
the “means” and the “ends.”130 The “ends” or the objective the 
government seeks to achieve must be actual and important. The 
“means” or the classification the government has used must be 
“substantially related” to the ends. Here, the means (the gender-
based reproductive health access exclusion) and the ends (pre-
sumably, reducing Medicaid spending by $4.7 billion between 
2006–2010) can be compared to United States v. Virginia, where 
the Supreme Court subjected Virginia Military Institute’s (“VMI”) 
male-only admissions policy to intermediate scrutiny.131 
The Court determined that Virginia’s male-only admis-
sions policy to VMI was not “substantially related” to the 
state’s objective of maintaining the adversative method, and the 
objective of educating “citizen soldiers” was not “substantially 
advanced by women’s categorical exclusion, in total disregard 
of their individual merit.”132 Likewise, the federal government’s 
gender-based reproductive health access exclusion in the DRA 
is not “substantially related” to the objective of spending reduc-
tion. For every tax dollar spent on contraceptive services, $3.00 
in Medicaid costs for pregnancy-related healthcare and medical 
care of newborns is saved, 1.3 million unplanned pregnancies are 
avoided, and without publicly supported services, there would be 
an annual increase of 40% more abortions.133 Furthermore, the 
DRA defies the purpose of other statutes, Title X and Medicaid, 
which have ensured women’s affordable access to oral contracep-
tives in relation to reproductive health and family planning for 
over a quarter of a century. When a heightened level of scrutiny is 
applied, economic reasons are not enough to uphold a statute as 
constitutional. Therefore, in terms of the DRA, the government 
has failed to demonstrate the requisite “exceedingly persuasive 
justification” for denying women access to affordable oral con-
traceptives to which they are entitled under federal law.134 
A final step in the “means/ends” analysis is the assess-
ment of the concepts of over-inclusiveness and under-inclusive-
ness. A law is over-inclusive when it applies to some situations 
that do not serve its objectives.135 Conversely, a law is under-
 inclusive when it “does not apply to some situations that do serve 
its objectives.”136 The DRA, although it contains no express 
language regarding gender differentiation and denial of access 
to oral contraceptives, can be seen as over-
 inclusive because it affects all women procur-
ing oral contraceptives from federally funded or 
campus health clinics, including those individu-
als not traditionally covered under the umbrella 
of Title X or Medicaid. There is a strong likeli-
hood that the classification will meet the appli-
cable means test.
As a matter of public policy, we, as a nation, want women 
to have affordable access to oral contraceptives. As a plurality 
of the Supreme Court acknowledged 35 years ago, “our Nation 
has had a long and unfortunate history of sex discrimination.”137 
 Public policy has been defined as “the principle of law which 
holds that no citizen can lawfully do that which has a tendency 
to be injurious to the public or against the public good.”138 Pre-
venting access to oral contraceptives for the treatment of medi-
cal conditions that inhibit women from being productive and 
efficient citizens, for family planning purposes, which in turn 
decreases abortion rates and government costs, and for discourag-
ing healthy living at every stage of life are acts that are injurious 
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to the public good.139 Therefore, as a matter of public policy, it is 
imperative that access to oral contraceptives at pre-DRA prices 
be reinstated.
b. remeDieS
The Supreme Court has held that 42 U.S.C. § 1983 
broadly construes a private federal right of action for damages 
and injunctive relief to redress violations by state officials of 
rights created by the United States Constitution as well as federal 
statutes.140 For example, a reading of the Public Health Service 
Act does not “reveal a precise or elaborate remedial scheme that 
would be obfuscated by allowing enforcement through a § 1983 
action.”141 Also, the statutory language and legislative history 
indicate an intent to improve and expand all aspects of family 
planning services by providing grants to public or nonprofit pri-
vate entities or state health authorities.142 Therefore, the Court in 
Planned Parenthood of Billings v. Montana concluded that the 
Public Health Services Act created federally enforceable rights 
in the plaintiffs and since no Congressional intent to preclude 
private enforcement existed, § 1983 provided a cause of action to 
remedy an alleged violation of the Act.143 
Relying on Supreme Court decisions, a U.S.  District 
Court recently held in Children’s Hosp. of Philadelphia v. 
 Horizon NJ Health that a hospital’s claims against an insurance 
provider for deprivation of constitutional rights in violation of 42 
U.S.C. § 1983 could proceed.144 The court noted that a symbiotic 
relationship was present because approximately 50% of funding 
received was federal and that the insurance company derived a 
substantial benefit.145 Additionally, the doctrine of third party 
standing and in turn associational standing was upheld because 
“the hospital had alleged facts sufficient to establish the third-
party standing of its doctors to bring their patients’ claims.”146 
Similarly, the DRA, because it is read in pari materia 
with Title X and Medicaid, creates federally enforceable rights 
in women who utilize clinics that qualify for federal funding 
and since no Congressional intent is presently precluding pri-
vate enforcement, § 1983 should be applicable. As in Children’s 
Hosp. of Philadelphia, a symbiotic relationship exists between 
the government and the pharmaceutical companies because the 
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drug manufacturers derive a substantial benefit from the billions 
of dollars the government expends annually on prescriptions.147 
In addition, Congress knew of the denial of access to oral con-
traceptives and has not passed any legislation or enforced correct 
application of the AMP formula.148 
The pharmaceutical companies’ interpretations of Sec-
tion 6001 of the DRA to no longer offer oral contraceptives to 
federally funded and campus health clinics based on the AMP 
formula is also possibly unconstitutional. Federal courts have 
held that private corporations that contract with the government 
may not be entitled to qualified immunity under § 1983.149 The 
Supreme Court, applying the nexus approach, held the appropri-
ate inquiry is “whether there is a sufficiently close nexus between 
the State and the challenged action of the regulated entity so that 
the action of the latter may be fairly treated as that of the State 
itself.”150 
Moose Lodge No. 107 v. Irvis is an instructive example of 
the application of the inquiry.151 Focusing on the state’s involve-
ment, the challenged action was the lodge’s racial discrimina-
tion against private guests.152 The Supreme Court emphasized 
that a nexus would exist and state action would be present, if the 
state had “fostered or encouraged” the allegedly unconstitutional 
action.153 Applying this reasoning to the DRA and the “business 
decisions” made by pharmaceutical companies, it could be found 
that a “sufficiently close nexus” between the State, the pharma-
ceutical companies and the potentially challenged action exists 
to impose liability on both the State and the private companies 
under § 1983.
concLusion
There is no comparable situation for men. Women’s 
overall healthcare is at issue and this type of funding reduction 
of medical treatment options promulgated by the DRA is con-
stitutionally invalid. As shown, cutting funding for oral contra-
ceptives has far reaching implications for women including the 
Deficit Reduction Act of 2005, which embodies the notion that 
what is not good policy is also not good politics.
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